Skip to main content
. 2021 Jul 13;151(10):3158–3167. doi: 10.1093/jn/nxab227

TABLE 1.

Baseline characteristics of participants classified by response to the intervention1

Characteristic HC-responders2 (n = 9) HF-responders2 (n = 6) Nonresponders (n = 13) Overall (n = 28)
Age, y 24.0 (22.0–30.0) 26.0 (22.0–34.0) 26.0 (22.0–30.0) 26.0 (22.0–34.0)
Men, n (%) 2 (22) 3 (50) 4 (31) 9 (32)
BMI, kg/m2 20.8 (18.2–28.1) 22.2 (19.6–24.0) 22.8 (17.2–31.9) 22.0 (17.2–31.9)
Waist circumference, cm 74.0 (67.0–91.0) 80.0 (70.0–91.0) 79.0 (64.0–101) 78.5 (64.0–101)
Drinking, No. (%)
 Occasionally 2 (22) 5 (83) 9 (60) 16 (57)
 Never 7 (78) 1 (17) 4 (40) 12 (43)
Fasting serum analyte
 Insulin, mU/L 26.3 (17.8–32.9) 24.3 (17.8–33.3) 24.8 (16.7–32.7) 25.5 (16.7–33.3)
 Glucose, mmol/L 4.21 (4.00–5.02) 4.32 (3.88–4.46) 4.16 (3.58–4.56) 4.21 (3.58–5.02)
 Triglycerides, mmol/L 0.54 (0.43–1.08) 0.76 (0.45–1.99) 0.69 (0.39–1.48) 0.65 (0.39–1.99)
 Total cholesterol, mmol/L 4.45 (3.60–5.44) 4.64 (3.61–6.47) 4.08 (3.00–5.17) 4.38 (3.00–6.47)
 LDL cholesterol, mmol/L 2.12 (1.26–2.77) 2.19 (1.15–3.57) 1.80 (1.12–2.67) 1.94 (1.12–3.57)
 HDL cholesterol, mmol/L 1.73 (1.27–2.17) 1.49 (1.23–2.63) 1.68 (1.14–2.08) 1.64 (1.14–2.63)
 ApoA1/apoB 1.92 (1.32–3.22) 1.55 (1.11–4.30) 2.10 (1.50–3.45) 2.05 (1.11–4.30)
 Albumin, g/L 42.3 (39.4–43.2) 43.5 (42.6–45.7) 40.8 (39.2–47.0) 42.4 (39.2–47.0)
 Creatinine, μmol/L 55.0 (46.0–70.0) 66.0 (54.0–76.0) 59.0 (46.0–76.0) 59.5 (46.0–76.0)
 AST, U/L 15.0 (13.0–19.0) 17.5 (12.0–22.0) 14.0 (11.0–21.0) 15.0 (11.0–22.0)
 ALT, U/L 11.0 (9.00–22.0) 15.0 (9.00–24.0) 9.00 (6.00–22.0) 10.5 (6.00–24.0)
 Uric acid, μmol/L 276 (187–450) 280 (242–417) 282 (163–400) 280 (163–450)
 Urea, mmol/L 3.70 (3.00–4.80) 3.95 (3.50–5.00) 4.00 (2.70–5.30) 3.80 (2.70–5.30)
1

Values are frequency (%) or median (range). ALT, alanine aminotransferase; AST, aspartate aminotransferase; HC, high carbohydrate; HF, high fat.

2

Responders for maximum postprandial glucose (MPG) or mean amplitude of glycemic excursions (MAGE).